Yang, Po-ShengPo-ShengYangLee, Yi-HsuanYi-HsuanLeeChung, Chi-FengChi-FengChungChang, Yuan-ChingYuan-ChingChangWang, Ming-YangMing-YangWangCHIAO LOTSAI, LI WEILI WEITSAIShih, Kuan-HuiKuan-HuiShihLei, JasonJasonLeiYu, Ben-LongBen-LongYuCheng, Skye HSkye HChengCHIUN-SHENG HUANG2021-09-102021-09-102019-12-181465-3621https://scholars.lib.ntu.edu.tw/handle/123456789/582572Background: The information of Oncotype DX applied in Asian breast cancer patients is limited. A recurrence index for distant recurrence (RI-DR) has been developed for early-stage breast cancer (EBC) from tumor samples in Chinese patients. In this study, we compared the prognostic performance of the Oncotype DX (ODx) recurrence score (RS) with the RI-DR for any recurrence risk type. Materials and methods: One hundred thirty-eight (138) patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative EBC who were previously tested with ODx were included for testing with the RI-DR. The cutoff score to partition the low- and high-risk patients was 26 for RS and 36 for RI-DR. The primary endpoint was recurrence-free survival (RFS). Results: The concordance between the RI-DR and RS was 83% in N0 patients and 81% in node-positive patients when the RS score cutoff was set at 26. With a median follow-up interval of 36.8 months, the 4-year RFS for the high- and low-risk groups categorized by the RS were 61.9% and 95.0%, respectively (hazard ratio: 10.6, 95.0% confidence interval [CI]: 1.8-62.9). The 4-year RFS in the high- and low-risk groups categorized by the RI-DR were 72.6% and 98.5%, respectively (hazard ratio: 18.9, 95% CI: 1.8-138.8). Conclusion: This paper illustrated the performance of RI-DR and ODx RS in breast cancer women in Taiwan. There was high concordance between the RI-DR and RS. The RI-DR is not inferior to the RS in predicting RFS in EBC patients. This study will fill the gap between the current and best practice in Chinese patients.enNanoStringbreast cancerdistant recurrencegene-expression profilingprognosis[SDGs]SDG3adult; aged; Article; BLM gene; BUB1B gene; C16ORF7 gene; cancer patient; cancer prognosis; cancer recurrence; cancer staging; CCNB1 gene; CCR1 gene; cohort analysis; confidence interval; controlled study; DDX39 gene; diagnostic test accuracy study; DTX2 gene; early cancer; ENSA gene; estrogen receptor positive breast cancer; female; follow up; hazard ratio; high risk patient; human; human epidermal growth factor receptor 2 negative breast cancer; human tissue; intermethod comparison; low risk patient; major clinical study; middle aged; MMP15 gene; NFATC2IP gene; OBSL1 gene; oncogene; oncological parameters; PIM1 gene; prediction; predictive value; progesterone receptor positive breast cancer; PTI1 gene; RCHY1 gene; recurrence index for distant recurrence; recurrence risk; recurrence score; sensitivity and specificity; STIL gene; Taiwan; TCF3 gene; TPX2 gene; TRPV6 genejournal article10.1093/jjco/hyz102312878832-s2.0-85076876865https://scholars.lib.ntu.edu.tw/handle/123456789/477690